On January 1, 2017 the government awarded National Export Trophy to export companies for the fiscal year 2013-14 for their outstanding performance in the country’s export earnings. Incepta Pharmaceuticals Ltd achieved export trophy in the pharmaceuticals products category. Our Chairman & Managing Director Mr. Abdul Muktadir received the trophy on behalf of Incepta Pharmaceuticals Ltd from Sheikh Hasina, the Hon'ble Prime Minister of the People's Republic of Bangladesh.

On January 1, 2017 the government awarded National Export Trophy to export companies for the fiscal year 2013-14 for their outstanding performance in the country’s export earnings. Incepta Pharmaceuticals Ltd achieved export trophy in the pharmaceuticals products category. Our Chairman & Managing Director Mr. Abdul Muktadir received the trophy on behalf of Incepta Pharmaceuticals Ltd from Sheikh Hasina, the Hon'ble Prime Minister of the People's Republic of Bangladesh.

As medicine progresses into a new era of personalized therapy, the use of monoclonal antibodies to treat a wide range of diseases lies at the heart of this new forefront. Monoclonal antibodies (mAb) are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies recognize and attach to specific proteins produced by cells. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting. Nowadays, there are approximately 30 monoclonal antibodies that have been approved for use in clinical practice in world market with many more currently being tested in clinical trials. Treatment landscape for monoclonal antibodies includes cancer, Osteoporosis, Rheumatoid Arthritis, Asthma, Psoriasis, Spondylitis, Inflammatory Bowel Disease etc.
Incepta pharmaceuticals Ltd, one of the leading pharmaceutical company in Bangladesh, is now manufacturing three monoclonal antibodies for the treatment of Osteoporosis, Rheumatoid Arthritis, Psoriasis, Spondylitis, Inflammatory Bowel Disease, Non Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia etc. Since its inception, Incepta has always pioneered in launching many first ever manufactured drugs in Bangladesh market. To continue its legacy, Incepta has launched 3 mAbs with brand name Relyto 100 & 500 (Rituximab), Denosis 60 & 120 (Denosumab) and Advixa (Adalimumab). True to its vision to become a trusted healthcare company that provides better health for everyone, everywhere, Incepta has launched these drugs to ensure better health for thousands of patients suffering from disease conditions like Osteoporosis, Arthritis, and Spondylitis etc.
Osteoporosis is a medical condition in which the bones become brittle and fragile from loss of tissue, typically as a result of hormonal changes, or deficiency of Calcium or vitamin D. Rheumatoid Arthritis is a chronic progressive disease causing inflammation in the joints and resulting in painful deformity and immobility, especially in the fingers, wrists, feet, and ankles. Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Lymphocytes are in the lymph nodes and other lymphoid tissues (such as the spleen and bone marrow) whereas chronic lymphocytic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Leukemia may affect red blood cells, white blood cells, and platelets. Thousands of patients are suffering from these debilitating diseases. Quality of life is significantly hampered, even the simplest tasks like drinking a glass of water becomes difficult. It is to be noted that Adalimumab is the best-selling drug in the world. Millions of patients worldwide are taking this mAbs for conditions like Rheumatoid Arthritis, Psoriasis, Spondylitis, Inflammatory Bowel Diseases etc. Denosumab is used for Osteoporosis and to reduce bone fracture risk in those who have risk factors. Relyto is used for Non Hodgkin’s lymphoma and chronic lymphocytic leukemia.
Incepta pharmaceuticals will continue to launch newer and better drug for the betterment of patients. Its pipeline includes many anticancer drugs including many mAbs and Tinibs. These drugs are known as targeted therapy for cancer. There are about 15 lakh cancer patients in Bangladesh, where about 2 lakh patients newly adding every year in this pool. In the coming years, the increase in population and longevity will result in an increase in the number of cancer patients in Bangladesh. With the launching of all these drugs Incepta hope to achieve new frontiers in cancer treatment regimen.

Incepta Vaccine Ltd has launched its vaccine bulk manufacturing facility in Savar, Dhaka. Honorable health Minister Mohammed Nasim, MP inaugurated the facility on Thursday, 28 July 2016.
Incepta Vaccine Ltd has developed an international standard bulk manufacturing facility providing the best environmental condition for performing the operations. The facility can manufacture both Bacterial and Viral bulk antigens. These will make us less dependent on vaccine import and help us to become a self-sufficient vaccine manufacturing country.
Addressing the inaugural ceremony, the minister said that Bangladesh is now able to export quality medicines to 90 countries all over the globe. Bangladesh is now capable of manufacturing life saving vaccine and successfully reduces the dependency on imported vaccines. ‘We will take the initiatives to get the WHO authorization which is needed for export of vaccines.’ The minister said.
Director General of Drug Administration, Major General Md Mustafizur Rahman and Secretary General of Bangladesh Association of Pharmaceutical Industries, SM Shafiuzzaman were also present there as special guests.

Antivenom injection is the preparation of snake venom antiserum. In Bangladesh, about 8000 snake bites occur annually with more than 20% mortality. Snake bite causes serious systemic or neurological complications such as bleeding disorder leading to fatal hemorrhage, permanent disability or death. Treatment of snake bite is neglected and is left to traditional ozha or kaviraj which lead to death. Snake venom antiserum is the mainstay of treatment after snake bite. But in Bangladesh, this life saving antiserum was not available everywhere in every season due to there is no local manufacturer and lack of cold chain system. Now Incepta Vaccine Ltd has introduced snake venom antiserum for the first time in Bangladesh with the brand name of Antivenom. Antivenom is manufactured by applying high tech lyophilization technology which is very stable and can be stored at room temperature. Antivenom is available in 10 ml vial. After reconstitution it should be given as infusion.

Incepta Pharmaceuticals launched the world’s first ever generic drug of Ledipasvir + Sofosbuvir tablet in Bangladesh market. In fact it is only generic drug of this combination available in world market. Since its launching it has generated huge interest throughout the world. Like previously launched Hopetavir (generic drug of Sofosbuvir), it was also launched at 99% discount price compared to innovator’s brand.
Twinvir is mainly indicated for the treatment of Hepatitis C genotype 1/4/6 infection. With this treatment option there is no need of either Interferon or Ribavirin. One tablet once a day is sufficient for the treatment of Hepatitis C. Twinvir provides high cure rate, less daily tablet burden, less complicated treatment regimens and also more affordable to the patients.
In addition to local market, Incepta hopes to launch this product to international market in near future.

On 03 February 2015, Incepta Pharmaceuticals Ltd launched the revolutionary oral drug Sofosbuvir for the treatment of Hepatitis C. It is the world’s first ever generic version of the drug Sofosbuvir and its brand name is Hopetavir. Incepta has beaten to the market a number of larger Indian competitors in the launching of generic Sofosbuvir tablet.
Previously, treatment of Hepatitis C was limited to Interferon alfa only. It is an injectable drug and thus is associated with many limitations such low efficacy rate, patients incompliance, side effects, high costs etc. With the launching of Sofosbuvir these limitations have now been minimized to a great extant. Sofosbuvir tablet shows greater than 90% efficacy rate, being an oral drug patient compliance has improved and it is now more affordable treatment option.
Incepta pharmaceuticals have launched this generic at almost 99% discount price of the innovator’s drug. Initially Incepta launched this drug in Bangladesh market. To date very few well controlled studies have been performed regarding the prevalence of hepatitis C in Bangladesh. In these studies 0.8-1% people of total population has been found to be carriers of hepatitis C virus.
Globally more than 170 million people are infected with the fatal disease hepatitis C. In near future the company aims to sell the drug overseas, including parts of Southeast Asia and Africa. Bloomberg has reported that the World Health Organization (WHO) is considering reviewing Hopetavir under its prequalification program, which could make the drug available in countries where innovator brand lacks patent protection and to humanitarian groups such as Médecins Sans Frontières (MSF).

Anti rabies vaccine is recommended as soon as possible after exposure to rabid animal to prevent rabies. However, in severe cases like WHO category-III bite only anti rabies vaccine is not enough to save life. In this case rabies immunoglobulin is recommended by WHO to ensure immediate protection. In Bangladesh, this life saving rabies immunoglobulin was imported, which was expensive and not available everywhere. Now Incepta Vaccine Ltd, a sister concern of Incepta Pharmaceuticals Ltd has introduced Rabies Immunoglobulin first time in Bangladesh with the brand name of Rabix-IG. Rabix-IG is available in 5 ml vial that can be given intramuscularly.

Tetanus antitoxin provides immediate protection against tetanus in tetanus prone wounds that can be happened in our life any time. About 73% cases of tetanus infection are caused by acute injuries or wounds. Bangladesh was fully dependent on imported tetanus antitoxin to prevent this deadly disease. Now Incepta Vaccine Ltd, a sister concern of Incepta Pharmaceuticals Ltd has introduced Tetanus antitoxin first time in Bangladesh with the brand name of Vaxitet-IG. Vaxitet-IG is available in 1 ml vial that can be given intramuscularly or subcutaneously.

A protocol agreement was signed between Incepta Pharmaceuticals Ltd and the Department of the Public Health of the Republic of Belarus for co-operation and production of pharmaceuticals. Prime Minister of the Republic of Belarus Mikhail V. Myasnikovich, Gennady Godovalnikov, Deputy Minister, Director of the Department of Pharmaceutical Industry, Ministry of Health, Republic of Belarus, AMA Muhith, Finance Minister of the People's Republic of Bangladesh, Abdul Muktadir, Managing Director of Incepta Pharmaceuticals Ltd and high officials of both countries were present in this occasion.

In his speech, honorable Minister of Health & Family Welfare Prof. Dr. A. F. M. Ruhal Haque said “I am appreciating such initiative of Incepta Vaccine Ltd. At present our Government needs to spend several hundred crore Taka to import the necessary vaccines for EPI program. But, now we can save huge amount of foreign currency for such initiative of Incepta Vaccine Ltd.” Honorable Minister also visited the newly constructed 3 stored vaccine facilities which consist of 75000 square-feet, animal house which is required to ensure the efficacy of manufactured vaccines and also cold chain system which is important to maintain the efficacy of vaccine. He appreciated much to see such a world class vaccine plant and its facilities.
National Professor M. R. Khan said “Incepta has been supplying medicine of supreme quality from its inception. Their initiative makes a remarkable appreciation to reduce the dependency on foreign medicine.”
Abdul Muktadir, Managing Director of Incepta Vaccine Ltd said “in the near past we had to import essential vaccines from foreign countries. But now we are manufacturing vaccines in our own country. We have constructed a totally new and enormous vaccine plant according to the guidelines of WHO GMP.” He also said “the annual production capacity of our vaccine plant is about 18 crore vials which will not only fulfill the annual demand of EPI program but also provide us the opportunity to export these vaccines in the foreign countries.”
In conclusion, Mr. Muktadir promised to make all these high-tech and life saving vaccines available and affordable for the people of our country and sought overall assistance from the Government of Bangladesh for such endeavor.
Incepta Vaccine Ltd is the first Human vaccine company in Bangladesh, developed with primary objective to provide preventive medicine to vast majority of population at an affordable price. It is a new state of the art facility to manufacture vaccine in Bangladesh for the first time. The facility is fully compliant with WHO GMP guidelines. It has the following unique features:

• Four German filling lines, independent of each other so that four different products can be manufactured simultaneously. Each area has dedicated HVAC system to prevent cross contamination. All the filling area rooms are equipped with terminal HEPA filters, with required air changes so as to create Class A, B, C & D environment, as the requirement of GMP. Each filling line has a sterilizing autoclave and decontamination autoclave. Each line is connected to independent visual inspection and labeling machine so as to prevent the chances of cross contamination
• It has an advanced fully GMP compliant R&D facility which can independently handle several projects simultaneously involving bacteria and virus.
• It has well equipped microbiology and chemical laboratory.
• It also has a large lab animal house covering around 24,000 square feet area which has bio safety level 2 standard lab for testing of various vaccines which involve challenge with infectious organisms.
• It has unique cold chain system to maintain the required temperature in every step of filling to packaging. It has well designed spacious cold rooms to store raw materials and finished products. It has 4 cold rooms of temperature within 2-8 °C and 2 cold rooms of temperature -20 °C to store raw materials and finished products.

Incepta Vaccine Ltd can produce any dose size from 0.1ml to 15 ml, with 4 different products simultaneously and has capacity to fill more than 2,40,000 ampoules and 3,60,000 vials per day. The yearly capacity is 180 million vials and ampoules. To conduct the immunization program of EPI, yearly demand of vaccine is 21 million vials and other than EPI yearly demand is 10 million vials which is increasing day by day. The production capacity of this facility is enough to meet the local demand and export.

Incepta Vaccine Ltd is now manufacturing and marketing Typhoid vaccine (Vaxphoid), Rabies vaccine (Rabix-vc) and Tetanus vaccine (Vexitet). In near future Hepatitis B, Polio, Measles, Rubella, Tetanus antitoxin, Rabies immunoglobulin, Pentavalent and all other necessary vaccines will be manufactured. Incepta Vaccine Ltd is committed to provide all high tech life saving vaccines to the people at affordable price.

Hepatitis B virus infection is one of the major burdens for Bangladeshi people. More than 10 million people are suffering from hepatitis B virus infection. Moreover, Bangladesh was fully dependent on imported vaccine to prevent this deadly infectious disease. Now Incepta Vaccine Ltd, a sister concern of Incepta Pharmaceuticals Ltd has introduced Hepatitis B vaccine first time in Bangladesh with the brand name of Hepa-B. Hepa-B is available in vial of 0.5 ml for pediatric and 1 ml for adult that can be given intramuscularly.

Incepta Vaccine Ltd, a sister concern of Incepta Pharmaceuticals Ltd has introduced tetanus vaccine in Bangladesh market with the brand name of Vaxitet. Tetanus vaccine (Vaxitet) will help to save millions of neonates and mother from life threatening tetanus. Vaxitet will be available to patients at affordable price in 0.5 ml ampoule and can be given intramuscularly.

Incepta Vaccine Ltd, a sister concern of Incepta Pharmaceuticals Ltd has introduced life saving rabies vaccine in Bangladesh market with brand name Rabix-vc. In Bangladesh, more than 2000 people die from rabies every year which is highest in the world. But acute shortage, counterfeit, inadequate availability of imported vaccine, doubt with potency of vaccine due to improper maintenance of cold chain during transportation and high cost are major drawback to prevent this deadly disease. Now Incepta has stepped forward to manufacture high quality and affordable rabies vaccine in Bangladesh market. Rabix-vc is marketed in 1 ml vial which can be given intramuscularly.

Every year Bangladesh Government has to purchase more than 90 million doses of different vaccines to initiate the Expanded Program on Immunization (EPI) for children of 0-1 year. In private sector other than EPI, every year more than 30 million doses are required. This quantity is increasing day by day. Huge foreign currency is spent to purchase these vaccines. Since its inception, Incepta is always trying to fill up the therapeutic gap by providing the newer and modern needful medicines. Incepta Vaccine Ltd, a sister concern of Incepta Pharmaceuticals Ltd introduced first vaccine Vaxphoid, a vaccine to prevent typhoid fever which is one of the major causes of childhood death in Bangladesh.

Incepta Vaccine Ltd is the first Human vaccine company in Bangladesh, developed with primary objective to provide preventive medicine to vast majority of population at an affordable price. It is a new state of the art facility to manufacture vaccine in Bangladesh for the first time. The facility is fully compliant with WHO GMP guidelines. It has an advanced fully GMP compliant R&D facility which can independently handle several projects simultaneously involving bacteria and virus. Incepta has well equipped microbiology and chemical laboratory, a large lab animal house covering around 24,000 square feet area which has bio safety level 2 standard for testing of various vaccines.
Incepta has unique cold chain system to maintain the required temperature in every step of filling to packaging. It has well designed spacious several cold rooms to store raw materials and finished products. It has 4 cold rooms of temperature within 2-8 °C and 2 cold rooms of temperature -20 °C to store raw materials and finished products.

In near future, Rabies, Tetanus, Hepatitis B, Polio, Measles, Rubella, Tetanus antitoxin, Rabies immunoglobulin, Pentavalent and all other necessary vaccines will be manufactured. Incepta Vaccine Ltd is committed to provide all high tech life saving vaccines to the people of Bangladesh at affordable price.

UK MHRA, the regulatory authority of England inspected the Zirabo plant of Incepta Pharmaceuticals Ltd in February 2011. Incepta received the GMP approval certificate for its solid dosage form facility on 20th July 2011 for its own formulated products allowing marketing in UK and other European countries.

A contract manufacturing agreement has been signed between Sanofi-Aventis Bangladesh Limited and Incepta Pharmaceuticals Ltd. Under this agreement Incepta shall manufacture and supply Sanofi-Aventis Bangladesh Limited one of its global brands Clexane. An inspection team from Sanofi-Aventis France visited Incepta Pharma in 2010 to audit the prefilled syringe filling facility. After being fully satisfied with the Quality Management System (QMS) of Incepta the agreement was signed.

Incepta Vaccine Limited, a sister concern of Incepta Pharmaceuticals Ltd received GMP certificate from the Directorate General of Drug Administration, Ministry of Health & Family welfare, Government of the Peoples Republic of Bangladesh.

Directorate General of Drugs and Pharmaceuticals, Ministry of Health of the Republic of Turkey issued GMP certificates to Incepta Pharmaceuticals Ltd. for Tablets, Capsules and Lyophilized Products. Unlike single product GMP which is the normal trend, Incepta received GMP for multiple full lines.

The Head Office of Incepta was shifted to its newly purpose built building located in Tejgaon, Dhaka. Incepta started its Head Office operation from a rented space in Shantinagar, Dhaka on 1st of August 1999. With the growth of the company it became necessary to have bigger space for smooth operation. Incepta group bought a piece of land in the center of Dhaka city at Tejgaon. By September 2007, the office space was ready for operation. Apart from the Head Office, this multipurpose building also houses the Dhaka Sales office, Central Warehouse and Dhaka Depot operations.

The achievements of Pharmaceutical industry in last few years are undoubtedly praise worthy. On this succession accreditation with European GMP (Good Manufacturing Practice) certification by Incepta Pharmaceuticals Ltd. will create a new era in exporting pharmaceutical products. Dr. A M M Shawkat Ali, Honorable advisor, Ministry of Health and Family Welfare and Ministry of Food and Disaster Management, addressed this on a program organized by Incepta Pharmaceuticals Ltd. on 14th March at Hotel Sonargaon on the occasion of receiving European GMP (Good Manufacturing Practice) certification. The pharmaceutical industry has created tremendous potentiality to earn foreign currency, he added. He assured all the possible assistances from the Government to add muscle in this particular sector.

According to Mr. Abdul Muktadir, Incepta has earned remarkable goodwill both home and abroad in manufacturing high quality medicine. On this succession the achievement of this GMP certificate from European Commission has created new possibilities. The respect and position of local pharmaceutical industry will enhance to a great extent internationally by this achievement and the scope of exporting will be higher than ever before. Entrepreneurs and top management of many Pharma companies, renowned physicians, reputed pharmacists, representatives of foreign embassies, and civil society were also present in the evening.

To mention, by exporting in 19 countries, Incepta is not only bringing fame for the country, but also contributing remarkably in the development of national economy by earning foreign remittance. Incepta Pharmaceuticals Ltd. received accreditation with the European GMP certification on 11th January this year which will allow the company to export in all the countries of European Union and this certification is first ever for any local company.

Diabetes is now a major health concern around the world as well as in Bangladesh. Millions of these diabetes patients are now insulin dependent. Incepta introduced Human Insulin (rDNA), Maxsulin for the first time in Bangladesh pharmaceutical market on September 7th 2007. Incepta introduced Insulin at an affordable price maintaining high quality.

Incepta introduced Pantoprazole lyophilized injections (Pantonix IV) in the Bangladesh pharmaceutical market on June 6th 2007. Lyophilization technology is used to manufacture products that are sensitive to temperature and moisture. Lyophilization allows for greater stability, solubility and ensures desired therapeutic benefits to the patients. Through this launching Incepta became the first company in Bangladesh to manufacture and market fake rolex products.

Bio-tech products are the future trend in Pharma. Understanding the importance of bio-tech products in life science, Incepta focused on introducing these products at an affordable cost maintaining high quality. Through the introduction of Enoxaparin Sodium in the market Incepta became the pioneer in bio-tech product manufacturing in Bangladesh.

US Deputy Chief of Mission to Bangladesh, Ms. Judith A. Chammas visited Incepta Pharmaceuticals Ltd. factory at Zerabo, Savar on Monday, May 8, 2006. She was accompanied by Mr. S.M. Shafiuzzaman, President of Bangladesh Association of Pharmaceutical Industries. The guests were received by Managing Director Mr. Abdul Muktadir and other high officials of the company. Mr. Muktadir appraised the delegates about vision, present status and prospects of company in manufacturing the pharmaceutical products not only for the country but also for meeting the global needs.

Later on the envoy went around the production area of the plant while she was briefed by the Director Technical Operations Mr. Mahbubul Karim on international standard manufacturing facilities including quality management systems of the factory. The envoy expressed her satisfaction on observing the infrastructure and facilities. In her short opinion to the press personnel she also hoped about Incepta's successful contribution in export.

During the program, all other Directors of Incepta Pharmaceuticals Limited were also present.

US Deputy Chief of Mission to Bangladesh, Ms. Judith A. Chammas being given a memento by Incepta Pharmaceuticals Limited Managing Director Abdul Muktadir during her visit to the factory on Monday, May 8, 2006

Incepta Pharmaceuticals Ltd received the Enterprise of the Year 2004 Award. The Bangladesh Business Awards 2004 were presented yesterday to honour the businesspersons and enterprises for their outstanding performance last year.rnrnIncepta Pharmaceuticals Ltd received the Enterprise of the Year 2004 Award while Selina Quader received the award for Outstanding Woman in Business of the Year 2004.rnrnUnilever Bangladesh Limited got the Special Achievement Award 2004 and Kazi Zahedul Hasan was adjudged the Business Person of the Year 2004.rnrnJointly introduced by The Daily Star and DHL Worldwide Express five years ago, the awards are given every year in recognition of excellence of enterprises and individuals in different fields of business to felicitate and inspire them.rnrnBritish High Commissioner in Dhaka Anwar Choudhury announced the name of the Enterprise of the Year while Rokia A Rahman, former adviser to the caretaker government and president of Women Entrepreneurs' Association, Bangladesh, named the Outstanding Woman in Business of the Year 2004. rnrnUS Ambassador Harry K Thomas announced the name of the Special Achievement Award winner and Square Group Chairman Samson H Chowdhury named the Business Person of the Year at a gala ceremony at the Sonargaon Hotel ballroom in the city.

Diplomats, business leaders and magnates, entrepreneurs, intellectuals, professionals and government officials attended the function.rnrnAs the names of award winners were announced one by one amid pin-drop silence, the audience burst into applause congratulating the business heroes. Two giant screens displayed their exemplary successes in brief.rnrnReceiving the Enterprise of the Year 2004 Award on behalf of Incepta Pharmaceuticals Ltd, its Managing Director Abdul Muktadir said his company is a research-based pharmaceuticals company and has achieved unprecedented growth in the recent years.rnrnExpressing her reaction to winning the Outstanding Woman in Business of the Year 2004 Award, Agroconcern Proprietor Selina Quader said it was the first recognition of her endeavours. She was sure the award would encourage more women to enter the world of business. rnrn"I started my business with a capital of only Tk 5,000, which by now has grown to Tk 20 million," she told the gala event.rnrnAfter receiving the Special Achievement Award on behalf of Unilever Bangladesh Limited, its Chairman and MD Sanjiv Mehta said his company is the second best performer in entire Asia. Mehta said his company has proved that business can grow in Bangladesh with ethical practices.rnrnUnilever has delivered a sustained double-digit growth at an average of nearly three times the country's GDP growth for the last six years, he told the function, and expressed his conviction that Bangladeshi enterprises can manufacture world-class products. rnrnKazi Farms Group MD Kazi Zahedul Hasan, who was awarded as the Business Person of the Year 2004, said his company deals with around 60,000 farmers of the country. He said, "We recently have started exporting hatching eggs to Saudi Arabia, thereby adding a new item in the country's export basket."

Earlier, The Daily Star Editor Mahfuz Anam observed that a silent revolution has taken place in Bangladesh led by the entrepreneurs who are creating wealth for the nation. "It's a tremendous success of our entrepreneurs that they have uplifted the country's image by popularising products bearing the seal 'Made in Bangladesh' in the global market. So, they do deserve recognition," he told the gathering. rnrnIn his speech, DHL Worldwide Express, Bangladesh Country Manager Desmond Quiah said the success the awardees have achieved in taking their enterprises to a new height proves that they see more than others do.

Incepta was audited by UNICEF authorities and the production site was found to comply with the required GMP standards. In March 2005 Incepta started supply of its products to UNICEF. The first supplied product was Cotrimoxazole tablets and suspension.

According to the pharmaceutical market research company IMS Incepta became the 5th largest pharmaceutical company among all local as well as multinational companies. This remarkable feat was achieved within 5 years of starting market operation. Not only that, by this time the company had become one of the most trusted and recognized name among the medical community in terms of quality.

Technical Director of Incepta Pharmaceuticals Ltd. Mr. Mahbubul Karim delivered speech on factory infrastructure and technical facilities to the distinguished guests. Managing Director of Incepta Pharmaceuticals Ltd. Mr. Abdul Muktadir pointed out chronology of Pharmaceutical Industry of Bangladesh and future prospects of medicine export. After presentation, Saudi delegates inspected the manufacturing area and quality control facilities of the black dresses for prom factory. Saudi health minister Dr. Hamad Bin Abdullah Al-Manea and other guests expressed their satisfaction on the present infrastructure of the factory. Concerned experts hope that Incepta Pharmaceutical Ltd. will contribute significantly in the export of medicine from Bangladesh. rnrnIn this occasion, Managing Director of Incepta Pharmaceuticals Ltd. presented crests and gifts to the honorable guests. Saudi high official delegates led by honorable Health Minister of Saudi Arabia Dr. Hamad Bin Abdullah Al-Manae came to Bangladesh on 18th September for an official visit. The guests visited Incepta and another national pharmaceutical industry at this time. Incepta Pharmaceuticals Ltd. is one of the leading pharmaceutical manufacturers in Bangladesh.

Incepta is the first national company in Bangladesh to build a state-of-the-art Cephalosporin facility in a completely separate building from that of the non-Cephalosporins. According to cGMP regulations, separate facility for Cephalosporin manufacturing is required to prevent cross contamination with other penicillin products or non beta-lactum products.

Incepta arranged a scientific seminar on 24th May, 2000 to launch its first major prescription product Osartil (Losartan Potassium) tablets in the Bangladesh market. The product was introduced in April, 2000. Osartil was also the first of the First Ever Products to come into the market from Incepta. According to the market research company IMS Osartil is now the # 1 Antihypertensive brand in the market.